By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

For the uninitiated, both Zepbound (tirzepatide) and Wegovy (semaglutide) are weight loss drugs. They target hormones that ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance.

Losing weight can be a challenge for many. With so many variables present in everyday life, including stress, lack of sleep, ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

Eli Lilly has partnered with direct-to-consumer health-care startup Ro to offer more affordable single-dose vials of its ...